Based in Germany, Ethris is a startup. Brouky records 3 investors associated with the company.
Ethris is a German biotechnology company developing mRNA-based therapeutics and vaccines using proprietary SNIM® RNA and SNaP LNP® delivery platforms. Its pipeline focuses on pulmonary indications such as asthma and rare lung diseases and on enabling thermostable, multi-route lipid nanoparticle delivery.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.